'Pharmaceutical Contract Sales Market Will Reach $3,912m in 2013' Predicts new Visiongain Report

Informations

• Publié par: visiongain
• Nombre de lectures: 31
• Langue: English

Extrait

'Pharmaceutical Contract Sales Market Will Reach $3,912m in 2013' Predicts new Visiongain Report

PR Newswire LONDON, November 13, 2012

LONDON,November 13, 2012/PRNewswire/ --

A new report byvisiongainpredicts that the global market forpharmaceuticalcontract sales will be worth$3,912min 2013. Between 2011 and 2017, the worldwide market w ill grow with a CAGR of over 8%. Demand for outsourced sales teams will drive growth during this decade. Those findings and others appear inWorld Pharmaceutical Contract Sales Market 2013-2023, published inNovember 2012. Visiongain is a business information provider based in London, UK.

Personal promotion will account for the largest proportion of pharma contract sales organisation (CSO) revenues throughout the 10-year forecast period. However, faster growth will come from other sectors of the contract sales market. Outsourcing of non-personal promotion will increase from 2012 to 2023, driven in the early years by greater use of teledetailing. Innovation and improvements to current technology will provide greater opportunities for virtual detailing. In 2023, outsourced edetailing will account for close to$200min CSO revenues, the report shows.

Richard Lang, a pharmaceutical industry analyst for visiongain, said: "Pharmaceutical sales models are changing rapidly. Healthcare payers have greater influence in prescribing decisions, complicating market access strategies for pharmaceutical companies. CSOs are expanding beyond traditional sales services to meet demand for market access expertise from pharmaceutical partners. Add-on services, such as medical education and patient compliance, will offer new sources of revenue for C SOs in the period 2013-2023.

"Our study forecasts the leading national pharmaceutical contract sales markets. In 2011, the US andEurope dominated the market, accounting for more than 75% of global revenues. However, market leaders, such as inVentiv Health, Quintiles and United Drug, already operate on a global scale. Recently these companies made advances into emerging markets, establishing offices in the BRIC nations (Brazil, Russia, India and China). Drug developers are increasingly interested in entering emerging markets, looking to take advantage of expanding healthcare coverage, rising wealth, and large patient populations. Outsourcing will provide local expertise in market access and sales models. Fast growth is forecast for all four of the BRIC nations, in terms of contract sales, to 2023."

World Pharmaceutical Contract Sales Market 2013-2023 provides original quantitative and qualitative analyses of the pharma contract sales market. It shows revenue forecasts to 2023 for the overall world market, submarkets and prominent national markets. It also identifies and discusses future trends likely to affect that industry and market. The study adds to visiongain's portfolio of analytical reports covering pharmaceutical outsourcing and service markets.

For further information concerning Visiongain's World Pharmaceutical Contract Sales Market 2013-2023 report please visithttp://www.visiongain.com/Report/928/World-Pharmaceutical-Contract-Sales-Market-2013-2023

Contact: Email: Sara Peerun [e-mail] Tel: [phone]

Companies Listed 360 Vantage Abbott Laboratories Across Health Actelion Pharmaceuticals Agência Nacional de Vigilância Sanitária (ANVISA) Akcess Akrikhin Allergan Alliance Healthcare (part of United Drug) Almirall Apple Ashfield Healthcare Ireland (part of United Drug) Ashfield Healthcare (part of United Drug) Ashfield In2Focus (part of United Drug) Ashfield KK (part of United Drug) Association of the British Pharmaceutical Industry (ABPI) Astellas Pharma

AstraZeneca Biogaran Blue Diesel (part of inVentiv Health) Boehringer Ingelheim Ministério da Saúde [Brazil] Business Edge Solutions and Training (BEST) Cegedim Strategic Data Celesio Centers of Medicare and Medicaid Services (CMS) [US ] Chinese Ministry of Health Cider Sante (part of Pharmexx) CMIC CMIC MPSS Co (part of CMIC) CMR Institute [US] Congressional Budget Office (CBO) [US] Consumer Advisory Group [UK] Corcept Therapeutics Daiichi Sankyo Dayarn Pharma Delcath Systems Depomed Drug Safety Alliance (DSA, part of United Drug) Eisai Eli Lilly European Commission (EC) European Federation of Pharmaceutical Industries and Associations (EFPIA) Evolve Selection Federation of Medical Representatives Association of India (FMRAI) Ferring Pharmaceuticals Food and Drug Administration (FDA) [US] Genentech (part of Roche) Go! Healthcare Marketing Grey Healthcare Group Group DCA (part of PDI) Grünenthal GSK Health Kare Pharma International (HKPI) Human Genome Sciences (part of GSK) IMS Health Informed Medical Communications Innovex (part of Quintiles) Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWiG) [Germany] International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Interpace BioPharma (part of PDI) inVentiv Health inVentiv Health Korea (part of inVentiv Health) inVentiv Health Selling Solutions (part of inVentiv Health) inVentiv Japan (part of inVentiv Health) inVentiv Recruitment Services (part of inVentiv Health) inVentiv Therapeutics Institute (part of inVentiv Health) Invida Iroko Cardio International Japan Contract Sales Organisation Association (JCSO A) Japan Pharmaceutical Manufacturers Association (JPM A) Kadrige Les enterprises du médicament (LEEM) [France] Leo Pharma LG Lupin Pharmaceuticals Marvecs MDS Co (part of CMIC) MELA Sciences Menarini Group Merck & Co. Merqurio Group Merqurio Pharma Ministerio de Sanidad, Servicios Sociales e Igualdad [Spain] Motorola MySTRO (part of inVentiv Health) National Health Service (NHS) [UK] National Institute for Health and Clinical Excellence (NICE) [UK] NATIVE NetworksMD/Pharmalink (part of Zuellig Pharma) Neurocrine Biosciences

Novartis Nycomed OnCall Oracle Organisation of Pharmaceutical Producers of India (OPPI) PDI PDI Voice (part of PDI) Pfizer Pharco Pharmaceuticals Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmakon Pharmartis Pharmexx (part of United Drug) Polpharma Proton Pharma Publicis Healthcare Communications Group Publicis Touchpoint Solutions Q.E.D. International (part of Quintiles) Qforma Quintiles Ramco Import Export Research in Motion (RIM) Roche Rottapharm Madaus Samsung Sanofi Santarus Scottish Medicines Consortium (SMC) Sermo Servier Shalaks Pharmaceuticals (part of Invida) Sinclair IS Pharma Sofip Stallergenes StayinFront Synopia Rx (part of United Drug) Temas Temasek Holdings The Royce Consultancy (part of Quintiles) Thomas H. Lee Partners Touchpoint Recruiting Solutions United Drug Universal WorldEvents Valeritas VCG Bio VCG & Associates Veeva Systems Vivus WPP Zuellig Group Zuellig Pharma

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies inEurope. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to [e-mail] call her on [phone]